$2.12
+0.03 (+1.44%)
Open$2.04
Previous Close$2.09
Day High$2.14
Day Low$2.04
52W High$3.24
52W Low$1.43
Volume—
Avg Volume201.4K
Market Cap181.88M
P/E Ratio5.17
EPS$0.36
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+2,091.5% upside
Current
$2.12
$2.12
Target
$46.46
$46.46
$33.82
$46.46 avg
$60.35
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 35.98M | 14.58M | 13.34M |
| Net Income | 35.50M | 2.88M | 3.22M |
| Profit Margin | -56.1% | 19.8% | 24.2% |
| EBITDA | 31.95M | 4.55M | 4.43M |
| Free Cash Flow | — | 4.06M | 3.77M |
| Rev Growth | — | -8.4% | -7.1% |
| Debt/Equity | — | 0.65 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |